Protocol Ledger

NCT05046795 · Phase III · COMPLETED

Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

Interventional Phase III clinical trial protocol NCT05046795 sponsored by Viatris in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-10 Enrollment: 258 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05046795
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)258 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05046795
Protocol FieldVerified Registry Value
NCT IdentifierNCT05046795
Consolidated Lead SponsorViatris
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment258 participants (ACTUAL)
Registered Start Date2021-11-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI